Nivika Chemo Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 4 Months
- Last Filing with ROC 31 Mar 2018
- Satisfied Charges ₹ 9.00 Cr
- Revenue Growth -0.62%
- Profit Growth 28.79%
- Ebitda
- Net Worth -17.95%
- Total Assets 2.28%
About Nivika Chemo Pharma
Nivika Chemo Pharma Private Limited (NCPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 September 2009 and has a history of 15 years and four months. Its registered office is in Vadodara, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹9.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Vipulkumar Patel and Ramaben Patel serve as directors at the Company.
Company Details
-
Location
Vadodara, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230GJ2009PTC058056
-
Company No.
058056
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Sep 2009
-
Date of AGM
29 Sep 2018
-
Date of Balance Sheet
31 Mar 2018
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Nivika Chemo Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vipulkumar Patel
|
Director | 09-Sep-2009 | Current |
|
Ramaben Patel
|
Director | 09-Sep-2016 | Current |
Financial Performance of Nivika Chemo Pharma.
Nivika Chemo Pharma Private Limited, for the financial year ended 2018, experienced Minor drop in revenue, with a 0.62% decrease. The company also saw a substantial improvement in profitability, with a 28.79% increase in profit. The company's net worth observed a substantial decline by a decrease of 17.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nivika Chemo Pharma?
In 2018, Nivika Chemo Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹90.00 M
Charges Breakdown by Lending Institutions
- The Mehsana Urban Co-Op. Bank Limited : 9.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Mar 2013 | The Mehsana Urban Co-Op. Bank Limited | ₹6.00 Cr | Satisfied |
| 08 Nov 2012 | The Mehsana Urban Co-Op. Bank Limited | ₹3.00 Cr | Satisfied |
How Many Employees Work at Nivika Chemo Pharma?
Unlock and access historical data on people associated with Nivika Chemo Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nivika Chemo Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nivika Chemo Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
